Status:
COMPLETED
Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937
Lead Sponsor:
Bellus Health Inc. - a GSK company
Conditions:
Healthy
Eligibility:
MALE
30-65 years
Phase:
PHASE1
Brief Summary
This is a single-centre, open-label, non-randomised, single-period, single-dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite ident...
Eligibility Criteria
Inclusion
- Healthy males
Exclusion
- History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder,as judged by the investigator
Key Trial Info
Start Date :
August 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 2 2021
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT05244759
Start Date
August 25 2020
End Date
March 2 2021
Last Update
February 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quotient Sciences
Nottingham, Ruddington, United Kingdom, NG11 6JS